FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907519508> ?p ?o ?g. }

• W2907519508 endingPage "2008" @default.
• W2907519508 startingPage "2008" @default.
• W2907519508 abstract "Abstract Introduction: Bortezomib-containing regimens (BCRs) have been the standard frontline approach for the treatment of transplant ineligible multiple myeloma (TIMM) patients in Canada for many years. Based on recent randomized clinical trial results lenalidomide and dexamethasone (Ld) has become another provincially funded option in Canada in the same therapeutic space. We aimed to compare the effect of BCRs and Ld for the treatment of TIMM using the newly-formed Myeloma Canada Research Network Multiple Myeloma Database (MCRN-MM-DB) project. This web-based centralized platform can track and characterize real-world outcomes of patients treated at major Canadian institutions and includes both legacy data dating back to 2007 (from 4 centres) as well as ongoing prospective data collection (from 11 centres) analyzed up to 01/07/18. Patients and Methods: The primary objective was to assess the ORR, PFS and OS for TIMM patients treated with CyBorD/CyBorP, Ld, VMP or VD/VP, each given as reported previously but with dose-adjustments at the discretion of the treating physician to maintain patients on therapy. The two-sided Fisher exact test was used to test for differences between categorical variables. Survival curves were constructed according to the Kaplan-Meier method and compared using the log rank test; a p value of <0.05 was considered significant. Results: 842 TIMM patients were evaluated. Clinical characteristics are shown in Table 1. Median OS and PFS for the entire cohort were 54.1 and 20.4 months, respectively. ORR and ≥VGPR better rates were 83% and 52% for the entire cohort. A ≥VGPR rate of 53%, 46%, 56% and 51% were observed for patients treated with CyBorD/P, VMP, Ld and VD/VP, respectively (p=0.3). The median PFS was longer for Ld patients (25 months) compared to CyBorD/CyBorP, VMP and Vd/VP (19.3, 20.5 and 13.7 months, respectively), (p=0.03, Fig 1a); there was no significant difference in PFS between the 2 different alkylating-agent containing regimens when combined with bortezomib + steroids (CyBorD/P vs VMP, p =0.9). Median OS was 51, 59.5, 29.4 and 66.5 months for those patients treated with CyBorD/CyBorP, VMP, VD/VP and Ld, respectively (p=0.07, Fig 1b). When the OS and PFS for CyBorD/P (typically given for a fixed duration of 9 cycles) were compared with Ld in a subset analysis, the p-values were 0.08 and 0.008, respectively. Conclusions: 1) OS was not significantly different in patients treated with either a bortezomib-containing triplet that includes an alkylator + steroid or continuous Ld. 2) The BCR triplets and Ld were more efficacious than the bortezomib + steroid doublet (VD/VP) for both OS and PFS although, the small sample size and adverse factors, such as frailty and comorbidities, may have influenced the findings. 3) The results in the real-world setting, i.e., a median PFS in the range of 1.5-2 years and median OS of 4.5-5.5 years, confirm triplet-based BCRs and Ld as current valid standards of care for frontline therapy in TIMM. 5) This study confirms the utility of a large comprehensive national database to benchmark current results for comparison with newer regimens as they are introduced into the Canadian therapeutic landscape. Disclosures Arleigh: Celgene: Honoraria; Janssen: Honoraria. Sebag:Janssen Inc.: Membership on an entity's Board of Directors or advisory committees; Amgen Canada: Membership on an entity's Board of Directors or advisory committees; Takeda Canada: Membership on an entity's Board of Directors or advisory committees; Celgene Canada: Membership on an entity's Board of Directors or advisory committees. Leblanc:Celgene Canada: Membership on an entity's Board of Directors or advisory committees; Janssen Inc.: Membership on an entity's Board of Directors or advisory committees; Amgen Canada: Membership on an entity's Board of Directors or advisory committees; Takeda Canada: Membership on an entity's Board of Directors or advisory committees. Louzada:Janssen: Honoraria; Celgene: Honoraria; amgen: Honoraria; pfizer: Honoraria. Venner:Janssen: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Amgen: Honoraria; Takeda: Honoraria." @default.
• W2907519508 created "2019-01-11" @default.
• W2907519508 creator A5001851529 @default.
• W2907519508 creator A5003468777 @default.
• W2907519508 creator A5023611212 @default.
• W2907519508 creator A5034837494 @default.
• W2907519508 creator A5038365893 @default.
• W2907519508 creator A5043490010 @default.
• W2907519508 creator A5046056355 @default.
• W2907519508 creator A5064547754 @default.
• W2907519508 creator A5064552806 @default.
• W2907519508 creator A5077619266 @default.
• W2907519508 creator A5082282800 @default.
• W2907519508 creator A5084969076 @default.
• W2907519508 creator A5085999045 @default.
• W2907519508 creator A5086115833 @default.
• W2907519508 date "2018-11-29" @default.
• W2907519508 modified "2023-10-17" @default.
• W2907519508 title "Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database" @default.
• W2907519508 doi "https://doi.org/10.1182/blood-2018-99-117363" @default.
• W2907519508 hasPublicationYear "2018" @default.
• W2907519508 type Work @default.
• W2907519508 sameAs 2907519508 @default.
• W2907519508 citedByCount "2" @default.
• W2907519508 countsByYear W29075195082019 @default.
• W2907519508 countsByYear W29075195082023 @default.
• W2907519508 crossrefType "journal-article" @default.
• W2907519508 hasAuthorship W2907519508A5001851529 @default.
• W2907519508 hasAuthorship W2907519508A5003468777 @default.
• W2907519508 hasAuthorship W2907519508A5023611212 @default.
• W2907519508 hasAuthorship W2907519508A5034837494 @default.
• W2907519508 hasAuthorship W2907519508A5038365893 @default.
• W2907519508 hasAuthorship W2907519508A5043490010 @default.
• W2907519508 hasAuthorship W2907519508A5046056355 @default.
• W2907519508 hasAuthorship W2907519508A5064547754 @default.
• W2907519508 hasAuthorship W2907519508A5064552806 @default.
• W2907519508 hasAuthorship W2907519508A5077619266 @default.
• W2907519508 hasAuthorship W2907519508A5082282800 @default.
• W2907519508 hasAuthorship W2907519508A5084969076 @default.
• W2907519508 hasAuthorship W2907519508A5085999045 @default.
• W2907519508 hasAuthorship W2907519508A5086115833 @default.
• W2907519508 hasBestOaLocation W29075195081 @default.
• W2907519508 hasConcept C10515644 @default.
• W2907519508 hasConcept C126322002 @default.
• W2907519508 hasConcept C143998085 @default.
• W2907519508 hasConcept C191093355 @default.
• W2907519508 hasConcept C2776063141 @default.
• W2907519508 hasConcept C2776364478 @default.
• W2907519508 hasConcept C2777478702 @default.
• W2907519508 hasConcept C2780401358 @default.
• W2907519508 hasConcept C2781413609 @default.
• W2907519508 hasConcept C66339696 @default.
• W2907519508 hasConcept C71924100 @default.
• W2907519508 hasConceptScore W2907519508C10515644 @default.
• W2907519508 hasConceptScore W2907519508C126322002 @default.
• W2907519508 hasConceptScore W2907519508C143998085 @default.
• W2907519508 hasConceptScore W2907519508C191093355 @default.
• W2907519508 hasConceptScore W2907519508C2776063141 @default.
• W2907519508 hasConceptScore W2907519508C2776364478 @default.
• W2907519508 hasConceptScore W2907519508C2777478702 @default.
• W2907519508 hasConceptScore W2907519508C2780401358 @default.
• W2907519508 hasConceptScore W2907519508C2781413609 @default.
• W2907519508 hasConceptScore W2907519508C66339696 @default.
• W2907519508 hasConceptScore W2907519508C71924100 @default.
• W2907519508 hasIssue "Supplement 1" @default.
• W2907519508 hasLocation W29075195081 @default.
• W2907519508 hasOpenAccess W2907519508 @default.
• W2907519508 hasPrimaryLocation W29075195081 @default.
• W2907519508 hasRelatedWork W1967461244 @default.
• W2907519508 hasRelatedWork W1999964913 @default.
• W2907519508 hasRelatedWork W2013163224 @default.
• W2907519508 hasRelatedWork W2530787370 @default.
• W2907519508 hasRelatedWork W2546436011 @default.
• W2907519508 hasRelatedWork W2751497063 @default.
• W2907519508 hasRelatedWork W2790617110 @default.
• W2907519508 hasRelatedWork W2802890120 @default.
• W2907519508 hasRelatedWork W2980910443 @default.
• W2907519508 hasRelatedWork W3134875278 @default.
• W2907519508 hasVolume "132" @default.
• W2907519508 isParatext "false" @default.
• W2907519508 isRetracted "false" @default.
• W2907519508 magId "2907519508" @default.
• W2907519508 workType "article" @default.